Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

• Main Authors: Dafna D. Gladman, MD (Author), Ana-Maria Orbai, MD (Author), Juan Gomez-Reino, MD (Author), Stacey Chang-Douglass, PhD (Author), Emanuele Leoncini, PhD (Author), Hannah E. Burton, MSc (Author), Keith S. Kanik, MD (Author), Ana Belen Romero, MD (Author), Joseph C. Cappelleri, PhD (Author), Ming-Ann Hsu, MPH (Author)
• Format: Book
• Published: Elsevier, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACT: Background: Tofacitinib and other new treatments approved for use in psoriatic arthritis have only recently been included in psoriatic arthritis treatment guidelines, and studies evaluating the relative efficacy of available therapies are important to inform treatment decisions by healthca...